S-1 in combination with CPT-11 plus trastuzumab for pretreated HER2+metastatic breast cancer

被引：0
|
作者：
Toh, U. [1 ]
Iwakuma, N. [1 ]
Mishima, M. [1 ]
Furukawa, M. [1 ]
Fujii, T. [1 ]
Ogo, E. [2 ]
Nakagawa, S. [3 ]
Tanaka, M. [4 ]
Akagi, Y. [1 ]
机构：
[1] Kurume Univ, Sch Med, Surg, Kurume, Fukuoka 830, Japan
[2] Kurume Univ, Sch Med, Radiol, Kurume, Fukuoka 830, Japan
[3] Natl Hosp Org, Kyushu Med Ctr, Breast Surg, Fukuoka, Japan
[4] Kurume Gen Hosp, Breast Surg, Kurume, Fukuoka, Japan
来源：
BREAST | 2015年 / 24卷
关键词：
D O I：
10.1016/S0960-9776(15)70059-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P008
引用
收藏
页码：S28 / S28
页数：1
相关论文
共 50 条
  • [41] NOVEL THERAPEUTIC MODALITY OF S-1 IN COMBINATION WITH CPT-11 TO OVERCOME 5-FLUOROURACIL RESISTANCE IN BLADDER CANCER
    Ide, Hiroki
    Kikuchi, Eiji
    Yasumizu, Yota
    Hattori, Seiya
    Hasegawa, Masanori
    Miyajima, Akira
    Oya, Mototsugu
    JOURNAL OF UROLOGY, 2010, 183 (04): : E376 - E376
  • [42] Randomized phase II study of CPT-11 versus PTX versus each combination chemotherapy with S-1 for advanced gastric cancer that is refractory to S-1 or S-1 plus CDDP: OGSG0701
    Kawase, Tomono
    Imamura, Hiroshi
    Goto, Masahiro
    Kimura, Yutaka
    Ueda, Shugo
    Matsuyama, Jin
    Nishikawa, Kazuhiro
    Sugimoto, Naotoshi
    Fujita, Junya
    Tamura, Takao
    Fukushima, Norimasa
    Kawakami, Hisato
    Sakai, Daisuke
    Kurokawa, Yukinori
    Shimokawa, Toshio
    Satoh, Taroh
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (10) : 1871 - 1880
  • [43] Randomized phase II study of CPT-11 versus PTX versus each combination chemotherapy with S-1 for advanced gastric cancer that is refractory to S-1 or S-1 plus CDDP: OGSG0701
    Tomono Kawase
    Hiroshi Imamura
    Masahiro Goto
    Yutaka Kimura
    Shugo Ueda
    Jin Matsuyama
    Kazuhiro Nishikawa
    Naotoshi Sugimoto
    Junya Fujita
    Takao Tamura
    Norimasa Fukushima
    Hisato Kawakami
    Daisuke Sakai
    Yukinori Kurokawa
    Toshio Shimokawa
    Taroh Satoh
    International Journal of Clinical Oncology, 2021, 26 : 1871 - 1880
  • [44] Complete response obtained and maintained by combination of S-1 and CPT-11 in hepatic metastases of colon cancer: A case report
    Tokunaga, Yukihiko
    Sasaki, Hirokazu
    Saito, Tohru
    ANTICANCER RESEARCH, 2008, 28 (3B) : 1837 - 1840
  • [45] COST-EFFECTIVENESS MODEL OF PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL COMPARED WITH TRASTUZUMAB IN COMBINATION WITH DOCETAXEL FOR THE 1ST LINE TREATMENT OF HER2+METASTATIC BREAST CANCER IN COLOMBIA
    Saenz, Ariza S. A.
    VALUE IN HEALTH, 2014, 17 (07) : A631 - A631
  • [46] Evolving HER2+Metastatic Breast Cancer Landscape
    Seidman, Andrew D.
    Bardia, Aditya
    Pegram, Mark
    Rao, Ruta
    ONCOLOGY-NEW YORK, 2021, 35 (12): : 839 - 842
  • [47] Efficacy, safety and tolerability of dual monoclonal antibody therapy with pertuzumab plus trastuzumab in HER2+metastatic breast cancer patients previously treated with trastuzumab
    Baselga, J.
    Imadalou, K.
    Paton, V
    Gray, D.
    Swain, S.
    CANCER RESEARCH, 2009, 69 (02) : 243S - 244S
  • [48] Health-related quality of life for margetuximab plus chemotherapy vs. trastuzumab plus chemotherapy in the phase 3 SOPHIA trial of patients with pretreated HER2+metastatic breast cancer
    Cardoso, Fatima
    Cortes, Javier
    Gradishar, William
    Im, Seock-Ah
    Pegram, Mark D.
    Rugo, Hope S.
    Wright, Gail S.
    De laurentiis, Michelino
    Levy, Christelle
    Ferrero, Jean-Marc
    Mansi, Janine
    Oyola, Raul
    Ricci, Francesco
    Jakobsen, Erik H.
    Uziely, Beatriz
    Egle, Daniel
    Giagounidis, Aristoteles
    Williams, Kirstin
    Hong, Shengyan
    Rock, Edwin
    Curigliano, Giuseppe
    CANCER RESEARCH, 2021, 81 (04)
  • [49] Relapsed/Refractory HER2+Metastatic Breast Cancer
    Brufsky, Adam M.
    Gadi, V. K.
    Hurvitz, Sara A.
    Iyengar, Neil M.
    ONCOLOGY-NEW YORK, 2021, 35 (04): : 215 - 219
  • [50] A randomized phase III trial of second-line chemotherapy comparing CPT-11 alone versus S-1 plus CPT-11 combination therapy in advanced gastric cancer refractory to first-line therapy with S-1 (JACCRO GC-05)
    Nishikawa, Kazuhiro
    Tanabe, Kazuaki
    Fujii, Masashi
    Kunisaki, Chikara
    Tsuji, Akihito
    Matsuhashi, Nobuhisa
    Takagane, Akinori
    Ohno, Tetsuro
    Kawase, Tomono
    Kochi, Mitsugu
    Yoshida, Kazuhiro
    Kakeji, Yoshihiro
    Ichikawa, Wataru
    Chin, Keisho
    Terashima, Masanori
    Takeuchi, Masahiro
    Nakajima, Toshifusa
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
12345